ResMed stock upgraded at RBC Capital Markets (RMD:NYSE)
· seekingalpha.com
ResMed (RMD) stock gains as RBC Capital Markets upgrades the company to Outperform and hikes target to $262, citing positives in its Q4 FY26 results. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...